ZYME has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZYME has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Zymeworks has the GF Score of 78, which implies that the company is Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
1. Financial Strength : 6/10Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Zymeworks is Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Zymeworks's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zymeworks's GF Score distribution charts can be found below:
* The bar in red indicates where Zymeworks's GF Score falls into.
Zymeworks (NAS:ZYME) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score | Performance Potential and All-in-One Screener Examples (1) |
91 - 100 | Highest outperformance potential |
81 - 90 | Good outperformance potential |
71 - 80 | Likely to have average performance |
51 - 70 | Poor future performance potential |
0 - 50 | Worst future performance potential, or not enough data |
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Thank you for viewing the detailed overview of Zymeworks's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Andrew Moore | officer: Chief Scientific Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Christopher Astle | officer: SVP & Chief Financial Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Kenneth Galbraith | director, officer: Chair & CEO | OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1 |
Carlos Campoy | director | 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Ecor1 Capital, Llc | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Miller Derek John Michael | director | 108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709 |
Neil A Klompas | officer: President & COO | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Lota S. Zoth | director | 334 CR 692, BUFFALO GAP TX 79508 |
Troy Cox | director | C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141 |
Kenneth J. Hillan | director | C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080 |
Hollings Renton | director | |
Kelvin Neu | director | 860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014 |
Natalie Sacks | director | C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710 |
Susan Mahony | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Neil Josephson | officer: Chief Medical Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
From GuruFocus
By Business Wire Business Wire • 12-21-2022
By Business Wire Business Wire • 01-04-2023
By Business Wire Business Wire • 10-20-2022
By Marketwired • 11-01-2023
By GuruFocus Research • 01-09-2024
By Marketwired • 10-16-2023
By Marketwired • 06-29-2023
By GuruFocus Research GuruFocus Editor • 12-15-2022
By Marketwired • 10-17-2023
By Business Wire Business Wire • 02-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.